ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 450

The Mucosal Anti-Citrullinated Protein Antibody Response in Pre-Clinical Rheumatoid Arthritis

Anneke van der Horst1, Ivy Y.K. Choi2, Dirkjan van Schaardenburg3, D.M Gerlag2, Paul Tak2, Dörte Hamann1 and Rogier M. Thurlings2, 1Sanquin Diagnostic Services, Amsterdam, Netherlands, 2Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, mucosal barriers and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose Recent data suggest rheumatoid arthritis (RA) may originate from an autoimmune response in inflamed mucosa. RA is associated with gingival and airway inflammation and alterations in the microbiomal composition in the gut. Furthermore, anti-citrullinated (cit) protein antibodies (ACPA) of the IgA class, the main secreted mucosal antibody, precede arthritis by years in a proportion of RA patients. When aiming to prevent arthritis it is critical to understand the source and regulation of autoantibody production in preclinical RA.

Objective to determine whether ACPA are produced at mucosal sites in ACPA positive individuals at risk for RA and to compare the ACPA isotype and fine specificity in mucosal fluids to peripheral blood.

Methods Saliva, sputum, faeces and peripheral blood were collected from 15 individuals with anti-cyclic cit protein (anti-CCP2) antibody positive arthralgia who are part of a cohort that is being prospectively followed for the possible development of arthritis. Saliva and sputum were collected during an early morning visit. Sputum was induced by inhalation of sodium chloride aerosols 4.5%. Mucus plugs were selected from sputum for extraction of supernatants. Faeces was collected at the same visit using stool collection kits and extracted using 6% BSA phosphate buffered saline. ACPA of IgA and IgG class were measured in mucosal fluids and blood using two cit fibrinogen peptides, one enolase peptide and one vimentin peptide and their respective arginine peptides as control.

Results Thirteen of 15 individuals tested positive for the anti-CCP2 test and ACPA in their blood at the day of mucosal fluid collection. Two patients tested positive for anti-CCP2 but negative for ACPA. Two other patients had high reactivity against both cit peptides and arginin controls and were also considered ACPA negative. Anti-cit fibrinogen, enolase and vimentin antibodies were detected in respectively 11, 4 and 3 individuals. The saliva of 4 patients contained IgA ACPA with positive tests for anti-cit enolase and anti-cit fibrinogen. The saliva of another patient tested positive for IgG anti-cit enolase and anti-cit fibrinogen. Other saliva, sputum and faeces samples tested negative for ACPA. All 5 patients with ACPA in saliva tested positive for the same antibodies in blood. In addition, in 3 of 5 patients ACPA were detected in blood that were not detected in saliva, including anti-cit fibrinogen, anti-cit vimentin and anti-cit enolase antibodies.

Conclusion Collection of saliva allows for the detection of ACPA in the saliva of a proportion of anti-CCP positive individuals at risk for RA. In these patients, IgG ACPA in blood are directed against more peptides compared to IgA ACPA in saliva. Future analyses should focus on further defining the precise source and regulation of mucosal ACPA compared to systemic ACPA. 

Acknowledgements The Dutch Reumafonds.


Disclosure:

A. van der Horst,
None;

I. Y. K. Choi,
None;

D. van Schaardenburg,
None;

D. M. Gerlag,
None;

P. Tak,
None;

D. Hamann,
None;

R. M. Thurlings,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-mucosal-anti-citrullinated-protein-antibody-response-in-pre-clinical-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology